Kymera Therapeutics KYMR Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's shares (diluted)?
- Kymera Therapeutics (KYMR) reported shares (diluted) of 97.5M in Q1 2026.
- How has Kymera Therapeutics's shares (diluted) changed year-over-year?
- Kymera Therapeutics's shares (diluted) increased by 21.7% year-over-year, from 80.1M to 97.5M.
- What is the long-term trend for Kymera Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Kymera Therapeutics's shares (diluted) has grown at a 15.2% compound annual growth rate (CAGR), from 188.4M to 332.4M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.